167 related articles for article (PubMed ID: 14651756)
1. The utility of cytokeratins 7 and 20 (CK7/20) immunohistochemistry in the distinction of short-segment Barrett esophagus from gastric intestinal metaplasia: Is it reliable?
Kurtkaya-Yapicier O; Gencosmanoglu R; Avsar E; Bakirci N; Tozun N; Sav A
BMC Clin Pathol; 2003 Dec; 3(1):5. PubMed ID: 14651756
[TBL] [Abstract][Full Text] [Related]
2. Cytokeratin expression patterns in noncardia, intestinal metaplasia-associated gastric adenocarcinoma: implication for the evaluation of intestinal metaplasia and tumors at the esophagogastric junction.
Shen B; Ormsby AH; Shen C; Dumot JA; Shao YW; Bevins CL; Gramlich TL
Cancer; 2002 Feb; 94(3):820-31. PubMed ID: 11857318
[TBL] [Abstract][Full Text] [Related]
3. Changing pattern of cytokeratin 7 and 20 expression from normal epithelium to intestinal metaplasia of the gastric mucosa and gastroesophageal junction.
Jovanovic I; Tzardi M; Mouzas IA; Micev M; Pesko P; Milosavljevic T; Zois M; Sganzos M; Delides G; Kanavaros P
Histol Histopathol; 2002 Apr; 17(2):445-54. PubMed ID: 11962749
[TBL] [Abstract][Full Text] [Related]
4. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach.
Ormsby AH; Goldblum JR; Rice TW; Richter JE; Falk GW; Vaezi MF; Gramlich TL
Hum Pathol; 1999 Mar; 30(3):288-94. PubMed ID: 10088547
[TBL] [Abstract][Full Text] [Related]
5. Utilization of cytokeratins 7 and 20 does not differentiate between Barrett's esophagus and gastric cardiac intestinal metaplasia.
Mohammed IA; Streutker CJ; Riddell RH
Mod Pathol; 2002 Jun; 15(6):611-6. PubMed ID: 12065774
[TBL] [Abstract][Full Text] [Related]
6. [Cytokeratin immunoreactivity patterns in the diagnosis of Barrett's esophagus].
Wang R; Xie J; Shen Y; Ren T
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Dec; 32(12):1820-3. PubMed ID: 23268419
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of cytokeratin immunoreactivity pattern for distinction of Barrett's esophagus from intestinal metaplasia of the stomach.
Iwata T; Kurita N; Nishioka M; Hidenori M; Wakatsuki S; Sano T; Shimada M
Hepatogastroenterology; 2007 Sep; 54(78):1710-2. PubMed ID: 18019700
[TBL] [Abstract][Full Text] [Related]
8. Barrett's esophagus and cardiac intestinal metaplasia: two conditions within the same spectrum.
White NM; Gabril M; Ejeckam G; Mathews M; Fardy J; Kamel F; Doré J; Yousef GM
Can J Gastroenterol; 2008 Apr; 22(4):369-75. PubMed ID: 18414711
[TBL] [Abstract][Full Text] [Related]
9. Interinstitutional variability and effect of tissue fixative on the interpretation of a Barrett cytokeratin 7/20 immunoreactivity pattern in Barrett esophagus.
Glickman JN; Ormsby AH; Gramlich TL; Goldblum JR; Odze RD
Hum Pathol; 2005 Jan; 36(1):58-65. PubMed ID: 15712183
[TBL] [Abstract][Full Text] [Related]
10. Cytokeratin 7/20 and MUC1, 2, 5AC, and 6 expression patterns in Barrett's esophagus and intestinal metaplasia of the stomach: intestinal metaplasia of the cardia is related to Barrett's esophagus.
Gulmann C; Shaqaqi OA; Grace A; Leader M; Patchett S; Butler D; Kay E
Appl Immunohistochem Mol Morphol; 2004 Jun; 12(2):142-7. PubMed ID: 15354740
[TBL] [Abstract][Full Text] [Related]
11. Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett's esophagus.
Ormsby AH; Vaezi MF; Richter JE; Goldblum JR; Rice TW; Falk GW; Gramlich TL
Gastroenterology; 2000 Sep; 119(3):683-90. PubMed ID: 10982762
[TBL] [Abstract][Full Text] [Related]
12. What is the role of cytokeratins in Barrett/cardia differentiation?
Younes M
Arch Pathol Lab Med; 2005 Feb; 129(2):181-2. PubMed ID: 15679416
[TBL] [Abstract][Full Text] [Related]
13. Phenotype of Barrett's esophagus and intestinal metaplasia of the distal esophagus and gastroesophageal junction: an immunohistochemical study of cytokeratins 7 and 20, Das-1 and 45 MI.
Glickman JN; Wang H; Das KM; Goyal RK; Spechler SJ; Antonioli D; Odze RD
Am J Surg Pathol; 2001 Jan; 25(1):87-94. PubMed ID: 11145256
[TBL] [Abstract][Full Text] [Related]
14. [Cytokeratin 7 and 20 in Barrett's esophagus].
Arra A; Nieva NB; Rey N; Fernández AO
Rev Fac Cien Med Univ Nac Cordoba; 2005; 62(3):57-62. PubMed ID: 16972735
[TBL] [Abstract][Full Text] [Related]
15. Cytokeratin and DAS-1 immunostaining reveal similarities among cardiac mucosa, CIM, and Barrett's esophagus.
DeMeester SR; Wickramasinghe KS; Lord RV; Friedman A; Balaji NS; Chandrasoma PT; Hagen JA; Peters JH; DeMeester TR
Am J Gastroenterol; 2002 Oct; 97(10):2514-23. PubMed ID: 12385432
[TBL] [Abstract][Full Text] [Related]
16. Distinction between short-segment Barrett's esophageal and cardiac intestinal metaplasia.
Liu GS; Gong J; Cheng P; Zhang J; Chang Y; Qiang L
World J Gastroenterol; 2005 Oct; 11(40):6360-5. PubMed ID: 16419166
[TBL] [Abstract][Full Text] [Related]
17. Cytokeratin 7 and 20 expression in intestinal metaplasia of the distal oesophagus: relationship to gastro-oesophageal reflux disease.
Shearer C; Going J; Neilson L; Mackay C; Stuart RC
Histopathology; 2005 Sep; 47(3):268-75. PubMed ID: 16115227
[TBL] [Abstract][Full Text] [Related]
18. Does Cytokeratin7/20 immunoreactivity help to distinguish Barrett's esophagus from gastric intestinal metaplasia? Results of a prospective study of 75 patients.
Schilling D; Spiethoff A; Rosenbaum A; Hartmann D; Eickhoff A; Jakobs R; Weickert U; Rebe M; Bohrer MH; Riemann JF
Pathol Res Pract; 2005; 200(11-12):801-5. PubMed ID: 15792123
[TBL] [Abstract][Full Text] [Related]
19. Cytokeratin immunoreactivity patterns in short-segment Barrett's esophagus in Japanese patients.
Yagi K; Nakamura A; Sekine A
J Gastroenterol Hepatol; 2005 Jun; 20(6):929-34. PubMed ID: 15946143
[TBL] [Abstract][Full Text] [Related]
20. Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology.
Couvelard A; Cauvin JM; Goldfain D; Rotenberg A; Robaszkiewicz M; Fléjou JF;
Gut; 2001 Dec; 49(6):761-6. PubMed ID: 11709508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
